PrepSolution

Nursing · Study journal

FNP Endocrine Practice Questions: Diabetes, Thyroid and Bone

Thirteen original FNP endocrine questions on ADA 2026 diabetes diagnosis and treatment, USPSTF thyroid and bone screening, and label rules for pioglitazone, empagliflozin and propylthiouracil.

By Elena R.Published Reviewed by PrepSolution Editorial Team10 min read
Inside this articleNursing
Section preview 01

Screening and diagnosis

Which adult meets the USPSTF criteria for prediabetes and type 2 diabetes screening?

Read this section
On this page

Endocrine items on the FNP boards lean on numbers: diagnostic cutoffs, A1C goals, ages for screening. The other half are drug-safety rules that decide whether a drug can be started at all. This set covers both, and stays away from the levothyroxine, alendronate and metformin items already in our pharmacology set.

The 13 questions are written for candidates using FNP-C exam prep. The NPCB blueprint gives Assess 32% of scored items and weights older and middle-aged adults most heavily, which is where most diabetes and thyroid questions sit. The AANP FNP exam blueprint guide breaks down the weighting.

This set is exam practice written from the guidelines, USPSTF recommendations and FDA labels listed under References. The questions are original PrepSolution items, not NPCB or ANCC exam questions. It is not clinical guidance for any patient, and it has not been reviewed by a credentialed nurse practitioner.

Screening and diagnosis

Question 1: Who to screen for diabetes

Which adult meets the USPSTF criteria for prediabetes and type 2 diabetes screening?

  • A. A 28-year-old with a BMI of 31
  • B. A 74-year-old with a BMI of 32
  • C. A 46-year-old with a BMI of 29
  • D. A 40-year-old with a BMI of 22 and no symptoms

Best answer: C. USPSTF recommends screening adults aged 35 to 70 who have overweight or obesity. A BMI of 29 is in the overweight range and 46 is inside the age band. Grade B.

  • A is not the best answer. At 28, the patient is younger than the USPSTF age range.
  • B is not the best answer. At 74, the patient is older than the USPSTF age range.
  • D is not the best answer. A BMI of 22 is not overweight, so this patient is outside the recommendation.

Question 2: One abnormal A1C

A 50-year-old without symptoms has an A1C of 6.7%. Glucose was not checked. What does ADA 2026 require before diagnosing diabetes?

  • A. A second abnormal result, either a repeat A1C or a different test such as fasting glucose
  • B. Nothing further; one A1C of 6.5% or more is diagnostic
  • C. An oral glucose tolerance test in every case
  • D. A repeat A1C in 12 months

Best answer: A. ADA criteria include an A1C of 6.5% or higher, but in the absence of unequivocal hyperglycemia, diagnosis requires two abnormal results, from different tests or from the same test at two time points. The two samples may be drawn at the same time.

  • B is not the best answer. Without unequivocal hyperglycemia, one result is not enough.
  • C is not the best answer. An OGTT is one option, not a requirement; a repeat A1C or a fasting glucose also confirms.
  • D is not the best answer. Confirmation should not wait a year.

Question 3: Prediabetes range

Which A1C result falls in the ADA range for prediabetes?

  • A. 5.4%
  • B. 5.6%
  • C. 6.6%
  • D. 6.1%

Best answer: D. ADA defines prediabetes by A1C as 5.7% to 6.4%. Only 6.1% falls inside that range.

  • A is not the best answer. 5.4% is below the prediabetes range.
  • B is not the best answer. 5.6% is just below the lower limit of 5.7%.
  • C is not the best answer. 6.6% is at or above the 6.5% diagnostic cutoff for diabetes.

Type 2 diabetes treatment

Question 4: A reasonable A1C goal

For many nonpregnant adults with diabetes and no problem hypoglycemia, which A1C goal does ADA 2026 call appropriate?

  • A. Below 6%
  • B. Below 7%
  • C. Below 8% for everyone
  • D. Below 9%

Best answer: B. ADA 2026 states that an A1C goal below 7% is appropriate for many nonpregnant adults without severe hypoglycemia or hypoglycemia affecting health or quality of life.

  • A is not the best answer. ADA does not set below 6% as the general goal.
  • C is not the best answer. Less stringent goals are individualized for specific people, not applied to everyone.
  • D is not the best answer. Below 9% is not the ADA goal for most adults.

Question 5: Diabetes with heart failure

A 67-year-old with type 2 diabetes and heart failure with preserved ejection fraction has an A1C of 6.9%. What does ADA 2026 recommend?

  • A. No change, because the A1C is at goal
  • B. Add a sulfonylurea
  • C. An SGLT2 inhibitor for glycemic management and prevention of heart failure hospitalization, irrespective of A1C
  • D. Add pioglitazone

Best answer: C. ADA recommends an SGLT2 inhibitor for adults with type 2 diabetes and heart failure, with reduced or preserved ejection fraction, for glycemic management and prevention of heart failure hospitalizations, irrespective of A1C.

  • A is not the best answer. The SGLT2 inhibitor recommendation applies irrespective of A1C.
  • B is not the best answer. A sulfonylurea has no heart failure benefit in the ADA recommendation.
  • D is not the best answer. Thiazolidinediones can cause or worsen heart failure, per the pioglitazone boxed warning.

Question 6: Pioglitazone and heart failure

Which patient should not be started on pioglitazone, per its label?

  • A. A patient with NYHA class III heart failure
  • B. A patient with an A1C of 8.2%
  • C. A patient already taking metformin
  • D. A patient with well-controlled hypertension

Best answer: A. The Actos label contraindicates starting pioglitazone in patients with established NYHA class III or IV heart failure. Its boxed warning says thiazolidinediones cause or worsen congestive heart failure in some patients.

  • B is not the best answer. An A1C above goal is a reason to intensify therapy, not a contraindication.
  • C is not the best answer. Combination with metformin is not a contraindication.
  • D is not the best answer. Controlled hypertension is not a contraindication.

Question 7: Empagliflozin in type 1 diabetes

A 26-year-old with type 1 diabetes asks whether empagliflozin could help lower his glucose. What does the Jardiance label say?

  • A. It is first-line in type 1 diabetes
  • B. It can replace insulin if A1C is near goal
  • C. It is safe in type 1 diabetes if eGFR is normal
  • D. It is not recommended for glycemic control in type 1 diabetes and may increase the risk of diabetic ketoacidosis

Best answer: D. The label lists as a limitation of use that Jardiance is not recommended to improve glycemic control in type 1 diabetes, because it may increase the risk of diabetic ketoacidosis.

  • A is not the best answer. The label specifically does not recommend it for glycemic control in type 1 diabetes.
  • B is not the best answer. Nothing in the label supports replacing insulin.
  • C is not the best answer. The type 1 limitation is not tied to kidney function.

Question 8: First eye exam in type 2 diabetes

A 49-year-old is diagnosed with type 2 diabetes today. When does ADA 2026 recommend the first dilated eye examination?

  • A. 5 years after diagnosis
  • B. At the time of diagnosis
  • C. Only if vision changes
  • D. When A1C exceeds 8%

Best answer: B. ADA recommends that people with type 2 diabetes have an initial dilated eye examination by an ophthalmologist or optometrist at the time of diagnosis. The 5-year delay applies to type 1 diabetes.

  • A is not the best answer. Five years after onset is the timing for adults with type 1 diabetes.
  • C is not the best answer. Screening is not symptom-triggered.
  • D is not the best answer. Timing is set by diagnosis, not by A1C.

Question 9: Foot evaluation

How often does ADA 2026 recommend a full foot evaluation for people with diabetes to find risk factors for ulcers and amputation?

  • A. Only when the patient reports numbness
  • B. Every 5 years
  • C. At least annually
  • D. Only after an ulcer has occurred

Best answer: C. ADA recommends a foot evaluation at least annually to identify risk factors for ulcers and amputations, including skin inspection, foot deformity assessment and neurological testing such as the 10-g monofilament.

  • A is not the best answer. The evaluation is routine, not symptom-triggered.
  • B is not the best answer. Every 5 years is far less often than the ADA recommendation.
  • D is not the best answer. The point of the evaluation is to find risk before an ulcer forms.

Thyroid and bone

Question 10: Screening TSH in an adult without symptoms

A healthy, nonpregnant 55-year-old without symptoms asks for a TSH "just to check." What is the USPSTF position on screening for thyroid dysfunction?

  • A. Evidence is insufficient to assess benefits and harms (I statement)
  • B. Screen all adults over 50 (Grade B)
  • C. Screen women only (Grade B)
  • D. Recommend against (Grade D)

Best answer: A. USPSTF concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults. It is an I statement.

  • B is not the best answer. USPSTF does not recommend routine screening at any age.
  • C is not the best answer. The statement does not differ by sex.
  • D is not the best answer. It is not a recommendation against screening; it is an insufficient-evidence statement.

Question 11: Neck ultrasound for thyroid cancer

A 38-year-old without symptoms or neck findings requests a thyroid ultrasound to screen for cancer. What does USPSTF recommend?

  • A. Screen with ultrasound every 3 years
  • B. Screen with ultrasound once
  • C. Insufficient evidence (I statement)
  • D. Recommend against screening for thyroid cancer in asymptomatic adults (Grade D)

Best answer: D. USPSTF recommends against screening for thyroid cancer in asymptomatic adults, concluding with moderate certainty that the harms outweigh the benefits. Grade D.

  • A is not the best answer. No screening interval is recommended because screening is recommended against.
  • B is not the best answer. A single screen is still screening, which USPSTF recommends against.
  • C is not the best answer. This topic has a D grade, not an I statement.

Question 12: Choosing an antithyroid drug

For which patient does the propylthiouracil label describe it as possibly the treatment of choice?

  • A. A 45-year-old man with Graves disease who tolerates methimazole
  • B. A 29-year-old who needs an antithyroid drug just before or during the first trimester of pregnancy
  • C. A 60-year-old who prefers once-daily dosing
  • D. A 12-year-old with newly diagnosed hyperthyroidism

Best answer: B. The boxed warning reports severe liver injury and acute liver failure with propylthiouracil. The label reserves it for patients who cannot tolerate methimazole and for whom radioactive iodine or surgery are not appropriate, and says it may be the treatment of choice when an antithyroid drug is needed during or just before the first trimester.

  • A is not the best answer. A patient who tolerates methimazole is not in the group for whom propylthiouracil is reserved.
  • C is not the best answer. Dosing preference is not a label reason to choose propylthiouracil.
  • D is not the best answer. The boxed warning describes liver injury in pediatric patients; the label does not make it a first choice for a child.

Question 13: Bone density in men

A healthy 72-year-old man with no fractures asks whether he should have a DXA scan. What is the USPSTF position on osteoporosis screening in men?

  • A. Screen all men 70 and older (Grade B)
  • B. Recommend against screening men (Grade D)
  • C. Evidence is insufficient to assess benefits and harms (I statement)
  • D. Screen men only after age 80

Best answer: C. USPSTF concludes that evidence is insufficient to assess the balance of benefits and harms of screening for osteoporosis in men. The B recommendations apply to women 65 and older and to younger postmenopausal women at increased risk.

  • A is not the best answer. There is no USPSTF B recommendation for men.
  • B is not the best answer. USPSTF does not recommend against screening men.
  • D is not the best answer. USPSTF sets no screening age for men.

Cutoffs and rules in this set

TopicRuleSource
Diabetes screeningAges 35 to 70 with overweight or obesityUSPSTF 2021 (B)
Diabetes diagnosisA1C 6.5% or more; two abnormal results unless hyperglycemia is unequivocalADA 2026, section 2
PrediabetesA1C 5.7% to 6.4%ADA 2026, section 2
A1C goalUnder 7% for many nonpregnant adultsADA 2026, section 6
Heart failureSGLT2 inhibitor irrespective of A1CADA 2026, section 9
Eye exam, type 2Dilated exam at diagnosisADA 2026, section 12
Foot evaluationAt least annuallyADA 2026, section 12
Thyroid dysfunction screeningInsufficient evidenceUSPSTF 2015 (I)
Thyroid cancer screeningRecommend againstUSPSTF 2017 (D)
Osteoporosis screening, menInsufficient evidenceUSPSTF 2025 (I)
Numbers and rules used above, with their source.

How should you use this set?

Most misses on endocrine items come from a cutoff that is close but wrong: 5.6% instead of 5.7%, a screening age band read one decade off, or a type 1 rule applied to type 2. Write the exact number next to each missed item. For the drug items, the label decides the answer, so check our FNP pharmacology practice set for levothyroxine, alendronate and metformin teaching points that this set leaves out. Women's osteoporosis screening is covered in the women's health set.

For timed questions across every domain on the blueprint, see FNP-C exam prep.

Elena R.

PrepSolution Content Editor, Nurse Practitioner Certification

About PrepSolution

References

  1. [1] ADA (2026). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2026. ADA. ADA
  2. [2] ADA (2026). 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes 2026. ADA. ADA
  3. [3] ADA (2026). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. ADA. ADA
  4. [4] ADA (2026). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes 2026. ADA. ADA
  5. [5] USPSTF (2021). Prediabetes and Type 2 Diabetes: Screening. USPSTF. USPSTF
  6. [6] USPSTF (2015). Thyroid Dysfunction: Screening. USPSTF. USPSTF
  7. [7] USPSTF (2017). Thyroid Cancer: Screening. USPSTF. USPSTF
  8. [8] USPSTF (2025). Osteoporosis to Prevent Fractures: Screening. USPSTF. USPSTF
  9. [9] FDA label (2026). Actos (pioglitazone). FDA label. FDA label
  10. [10] FDA label (2026). Jardiance (empagliflozin). FDA label. FDA label
  11. [11] FDA label (2026). Propylthiouracil tablets. FDA label. FDA label
  12. [12] NPCB (2026). FNP Candidate Handbook (June 2026). NPCB. NPCB

Help us improve this guide

How helpful was this article?

One tap helps us understand what’s useful.

Not helpful → Very helpful

Frequently asked questions

ADA uses an A1C of 6.5% or higher. Without unequivocal hyperglycemia, a second abnormal result is needed, either a repeat A1C or a different test such as fasting plasma glucose.

ADA defines prediabetes by A1C as 5.7% to 6.4%.

USPSTF recommends screening adults 35 to 70 who have overweight or obesity (Grade B).

ADA 2026 recommends an SGLT2 inhibitor for adults with type 2 diabetes and heart failure, reduced or preserved ejection fraction, irrespective of A1C.

USPSTF found the evidence insufficient to recommend for or against screening nonpregnant, asymptomatic adults for thyroid dysfunction.

No. They are original PrepSolution items written from the sources listed under References. They are not clinical guidance and have not been reviewed by a credentialed nurse practitioner.

Keep practicing for the FNP-C.

Review the study tools, access options and price, or start with free practice.

Related Articles